BACKGROUND: Immunosuppression for solid organ transplantation is associated with increased incidence of internal and cutaneous malignant tumors, among which skin cancer is the most common. OBJECTIVE: To determine the effects on cutaneous carcinogenesis when stopping therapy with immunosuppressive medications. OBSERVATIONS: We followed the clinical course of 6 solid organ transplant recipients after therapy with immunosuppressant medications was stopped because of allograft failure or unacceptable cutaneous carcinogenesis. Generally, we found that stopping therapy with immunosuppressive medications resulted in deceleration of cutaneous carcinogenesis, resolution of cutaneous verrucae vulgaris, and qualitative improvements in skin condition. Four patients experienced marked improvement; 2 did not. CONCLUSIONS: Cessation of transplant-associated therapy with immunosuppressive medications for patients in whom cutaneous carcinomas developed after transplantation may lead to deceleration of cutaneous carcinogenesis, decreased verrucae, and improved skin quality within 1 to 2 years. Because of the natural variation in skin cancer development and the small number of cases in this series, definitive conclusions require further study.
BACKGROUND: Immunosuppression for solid organ transplantation is associated with increased incidence of internal and cutaneous malignant tumors, among which skin cancer is the most common. OBJECTIVE: To determine the effects on cutaneous carcinogenesis when stopping therapy with immunosuppressive medications. OBSERVATIONS: We followed the clinical course of 6 solid organ transplant recipients after therapy with immunosuppressant medications was stopped because of allograft failure or unacceptable cutaneous carcinogenesis. Generally, we found that stopping therapy with immunosuppressive medications resulted in deceleration of cutaneous carcinogenesis, resolution of cutaneous verrucae vulgaris, and qualitative improvements in skin condition. Four patients experienced marked improvement; 2 did not. CONCLUSIONS: Cessation of transplant-associated therapy with immunosuppressive medications for patients in whom cutaneous carcinomas developed after transplantation may lead to deceleration of cutaneous carcinogenesis, decreased verrucae, and improved skin quality within 1 to 2 years. Because of the natural variation in skin cancer development and the small number of cases in this series, definitive conclusions require further study.
Authors: Sukirti Kalra; Ying Zhang; Elena V Knatko; Stewart Finlayson; Masayuki Yamamoto; Albena T Dinkova-Kostova Journal: Cancer Prev Res (Phila) Date: 2011-07-29
Authors: Robert P Carroll; David San Segundo; Kevin Hollowood; Teresa Marafioti; Taane G Clark; Paul N Harden; Kathryn J Wood Journal: J Am Soc Nephrol Date: 2010-01-28 Impact factor: 10.121
Authors: Jerry D Brewer; Oscar R Colegio; P Kim Phillips; Randall K Roenigk; M Amanda Jacobs; Diederik Van de Beek; Ross A Dierkhising; Walter K Kremers; Christopher G A McGregor; Clark C Otley Journal: Arch Dermatol Date: 2009-12
Authors: Terry H Wu; Karin Schreiber; Ainhoa Arina; Nikolai N Khodarev; Elena V Efimova; Donald A Rowley; Ralph R Weichselbaum; Hans Schreiber Journal: Cancer Immun Date: 2011-06-30
Authors: Christopher M Hope; Alexander Troelnikov; William Hanf; Shilpanjali Jesudason; Patrick T Coates; Peter S Heeger; Robert P Carroll Journal: Kidney Int Date: 2015-08-12 Impact factor: 10.612